ホーム / コンテンツ / Webinar / PBPK Modeling of Antibody-Drug Conjugates – Concept and Application

PBPK Modeling of Antibody-Drug Conjugates – Concept and Application

Live webinar

Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a cytotoxic anti-cancer drug directly to the tumor site with reduced off-target damage. ADCs combine the targeting capability of monoclonal antibodies with the cancer-killing capability of the payload (linker + cytotoxic drug). Virtual pharmacokinetic studies using the Simcyp Simulator physiologically-based pharmacokinetic (PBPK) modeling platform can inform first-in-human dose selection, concentration at the target site, and predict drug-drug interactions (DDIs) between the small molecule payload and other co-medications. Furthermore, the disposition of ADCs can be modeled in special populations for whom conducting clinical studies is challenging. This webinar will present the modeling capabilities of the Simcyp Biologics Simulator for ADCs and show how it can help drug development programs save time and money.

Register

Thank you for Registering!

Check out our Blog “Accelerating ADCs’ development pipeline using Simcyp PBPK

Our Speakers
Certara Felix Stader
Felix Stader
Senior Research Scientist

Felix Stader is a Senior Research Scientist at Certara UK. He studied biology and pharmaceutical science in Muenster (Germany) and did his PhD in Basel (Switzerland) about HIV drug pharmacokinetics and drug-drug interaction magnitudes in the elderly by using PBPK modeling. At Certara UK, Felix worked extensively on the biologics models of the Simulator including antibody-drug conjugates and the possibility to simulate therapeutic protein disposition in pediatrics. Additionally, Felix has broad experience in developing population and compound files.

Certara Himanshu
Himanshu Mishra
Himanshu Mishra serves as Director, Business Development for Certara’s Simcyp Division. Certara is the global leader in mechanistic modelling, which includes the renowned Simcyp Simulator for physiologically based pharmacokinetics (PBPK) and its Quantitative Systems Pharmacology (QSP) immunogenicity, immune-oncology, vaccine and gene therapy modelling & simulation platforms. Himanshu has a MBA and Master’s degree in Pharmacology and had previously worked at Certara as a Research Scientist supporting the development of the Simcyp PBPK Simulator. Himanshu has worked with various pharma and medical devices company in supporting and accelerating their technology transformation and digital strategy. He is a published author and avid traveller with a passion for how technology can accelerate drug development.
トップに戻る
Powered by Translations.com GlobalLink OneLink Software